Jonathan R Enriquez1, Shailja V Parikh1, Faith Selzer2, Alice K Jacobs3, Oscar Marroquin4, Suresh Mulukutla4, Vankeepuram Srinivas5, Elizabeth M Holper6. 1. Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX. 2. Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA. 3. Division of Cardiology, Boston University Medical Center, Boston, MA. 4. Division of Cardiology, University of Pittsburgh, Pittsburgh, PA. 5. Division of Cardiology, Jack D. Weiler/Montefiore Medical Center, Bronx, NY. 6. Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX. Electronic address: Elizabeth.Holper@UTSouthwestern.edu.
Abstract
BACKGROUND: Previous studies have demonstrated that patients with COPD are at higher risk for death after percutaneous coronary intervention (PCI), but other clinical outcomes and possible associations with adverse events have not been described. METHODS: Using waves 1 through 5 (1999-2006) of the National Heart, Lung, and Blood Institute Dynamic Registry, patients with COPD (n = 860) and without COPD (n = 10,048) were compared. Baseline demographics, angiographic characteristics, and in-hospital and 1-year adverse events were compared. RESULTS: Patients with COPD were older (mean age 66.8 vs 63.2 years, P < .001), more likely to be women, and more likely to have a history of diabetes, prior myocardial infarction, peripheral arterial disease, renal disease, and smoking. Patients with COPD also had a lower mean ejection fraction (49.1% vs 53.0%, P < .001) and a greater mean number of significant lesions (3.2 vs 3.0, P = .006). Rates of in-hospital death (2.2% vs 1.1%, P = .003) and major entry site complications (6.6% vs 4.2%, P < .001) were higher in pulmonary patients. At discharge, pulmonary patients were significantly less likely to be prescribed aspirin (92.4% vs 95.3%, P < .001), β-blockers (55.7% vs 76.2%, P < .001), and statins (60.0% vs 66.8%, P < .001). After adjustment, patients with COPD had significantly increased risk of death (hazard ratio [HR] = 1.30, 95% CI = 1.01-1.67) and repeat revascularization (HR = 1.22, 95% CI = 1.02-1.46) at 1 year, compared with patients without COPD. CONCLUSIONS: COPD is associated with higher mortality rates and repeat revascularization within 1 year after PCI. These higher rates of adverse outcomes may be associated with lower rates of guideline-recommended class 1 medications prescribed at discharge.
BACKGROUND: Previous studies have demonstrated that patients with COPD are at higher risk for death after percutaneous coronary intervention (PCI), but other clinical outcomes and possible associations with adverse events have not been described. METHODS: Using waves 1 through 5 (1999-2006) of the National Heart, Lung, and Blood Institute Dynamic Registry, patients with COPD (n = 860) and without COPD (n = 10,048) were compared. Baseline demographics, angiographic characteristics, and in-hospital and 1-year adverse events were compared. RESULTS:Patients with COPD were older (mean age 66.8 vs 63.2 years, P < .001), more likely to be women, and more likely to have a history of diabetes, prior myocardial infarction, peripheral arterial disease, renal disease, and smoking. Patients with COPD also had a lower mean ejection fraction (49.1% vs 53.0%, P < .001) and a greater mean number of significant lesions (3.2 vs 3.0, P = .006). Rates of in-hospital death (2.2% vs 1.1%, P = .003) and major entry site complications (6.6% vs 4.2%, P < .001) were higher in pulmonary patients. At discharge, pulmonary patients were significantly less likely to be prescribed aspirin (92.4% vs 95.3%, P < .001), β-blockers (55.7% vs 76.2%, P < .001), and statins (60.0% vs 66.8%, P < .001). After adjustment, patients with COPD had significantly increased risk of death (hazard ratio [HR] = 1.30, 95% CI = 1.01-1.67) and repeat revascularization (HR = 1.22, 95% CI = 1.02-1.46) at 1 year, compared with patients without COPD. CONCLUSIONS:COPD is associated with higher mortality rates and repeat revascularization within 1 year after PCI. These higher rates of adverse outcomes may be associated with lower rates of guideline-recommended class 1 medications prescribed at discharge.
Authors: Dennis T Ko; Lingsong Yun; Harindra C Wijeysundera; Cynthia A Jackevicius; Sunil V Rao; Peter C Austin; Jean-François Marquis; Jack V Tu Journal: Circ Cardiovasc Interv Date: 2010-03-23 Impact factor: 6.546
Authors: D O Williams; R Holubkov; W Yeh; M G Bourassa; M Al-Bassam; P C Block; P Coady; H Cohen; M Cowley; G Dorros; D Faxon; D R Holmes; A Jacobs; S F Kelsey; S B King; R Myler; J Slater; V Stanek; H A Vlachos; K M Detre Journal: Circulation Date: 2000-12-12 Impact factor: 29.690
Authors: Sameer K Mehta; Andrew D Frutkin; Jason B Lindsey; John A House; John A Spertus; Sunil V Rao; Fang-Shu Ou; Matthew T Roe; Eric D Peterson; Steven P Marso Journal: Circ Cardiovasc Interv Date: 2009-05-08 Impact factor: 6.546
Authors: Juan Zhao; Yun Zhang; David J Schlueter; Patrick Wu; Vern Eric Kerchberger; S Trent Rosenbloom; Quinn S Wells; QiPing Feng; Joshua C Denny; Wei-Qi Wei Journal: J Biomed Inform Date: 2019-08-22 Impact factor: 6.317
Authors: Robert M Reed; Michael Eberlein; Reda E Girgis; Salman Hashmi; Aldo Iacono; Steven Jones; Giora Netzer; Steven Scharf Journal: Am J Med Date: 2012-09-06 Impact factor: 4.965
Authors: Thomas Gaisl; Christian Schlatzer; Esther I Schwarz; Mathias Possner; Julia Stehli; Noriane A Sievi; Christian F Clarenbach; Damini Dey; Piotr J Slomka; Philipp A Kaufmann; Malcolm Kohler Journal: PLoS One Date: 2015-05-26 Impact factor: 3.240
Authors: Derrick Lopez; Judith M Katzenellenbogen; Frank M Sanfilippo; John A Woods; Michael S T Hobbs; Matthew W Knuiman; Tom G Briffa; Peter L Thompson; Sandra C Thompson Journal: Int J Equity Health Date: 2014-10-21
Authors: Pere Almagro; Anna Lapuente; Julia Pareja; Sergi Yun; Maria Estela Garcia; Ferrán Padilla; Josep L I Heredia; Alex De la Sierra; Joan B Soriano Journal: Int J Chron Obstruct Pulmon Dis Date: 2015-07-16